Purchase Order HHSN269201700167P
Award Date
1/18/17
Potential Completion Date
2/18/17
Potential Value
$144K
Federal Agency
NIH Clinical Center
Awardee
Profounda Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20892, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA), specifically Veterans Integrated Service Network (VISN) 20, to Profounda Inc. for the delivery of Impavido/Miltefosine, a critical medication used to treat leishmaniasis and other drug-resistant infections. The contract, valued at $16,650.00, does not have a set-aside designation and is intended to support the VA's mission of providing healthcare services to veterans by ensuring rapid access to...
This is a firm fixed-price purchase order contract awarded by the U.S. Department of Veterans Affairs (VA) to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The contract, valued at $49,950.00, is for the delivery of Impavido/Miltefosine, a critical medication used to treat leishmaniasis and other drug-resistant infections, to VA medical centers within the Veterans Integrated Service Network 20 (VISN 20). Profounda Inc. holds a...
This is a firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The contract, valued at $96,000.00, is for the delivery of Impavido/Miltefosine, a critical medication used to treat leishmaniasis and other drug-resistant infections, with a focus on providing emergency pharmaceutical solutions to veterans. Profounda Inc. has a...
This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs (VA) Veterans Health Administration (VHA) to Profounda Inc., a self-certified small disadvantaged business. The $49,950.00 contract is for the delivery of Profounda's Impavido/Miltefosine pharmaceutical product to the VA Sunshine Healthcare Network (VISN 20) in Orlando, Florida. Impavido/Miltefosine is used to treat leishmaniasis and other drug-resistant infections in veterans. This award is the latest in a...
This is a firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA) to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The contract, valued at $33,300.00, is for the delivery of Impavido/Miltefosine, a critical medication used to treat leishmaniasis and other drug-resistant infections. The contract has an ultimate completion date of January 8, 2025. Profounda Inc. has a significant Blanket Purchase Agreement...
The U.S. Department of Veterans Affairs (VA) has awarded a $49,950 firm fixed-price purchase order to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The contract is for the emergency delivery of 84 tablets of Impavido (Miltefosine) in three packages of 28, to the VA's Oklahoma City VA Medical Center (OKCVAMC) Pharmacy. This purchase order is part of a larger Blanket Purchase Agreement (BPA) valued at $1,127,000 that Profounda Inc. holds...
The Department of Veterans Affairs' Veterans Health Administration awarded a firm fixed-price purchase order to Profounda Inc., a self-certified small disadvantaged business, to provide Miltefosine drug with a potential value of $149,950.00. The order, placed under the VHA's Veterans Integrated Service Network 23, supports the agency's mission to deliver healthcare services to veterans by ensuring access to this specialized pharmaceutical product needed for treatment. Profounda has previously...
This is a firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA) to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The contract, valued at $99,900.00, is for the delivery of Miltefosine 50mg tablets, a critical medication used to treat leishmaniasis and other drug-resistant infections. This purchase order is part of a larger $1,127,000 Blanket Purchase Agreement (BPA) held by Profounda Inc. with the VA's...
This is a firm fixed-price purchase order awarded by the Department of Veterans Affairs' (VA) Veterans Health Administration (VHA) to Profounda Inc., a self-certified small disadvantaged business and manufacturer. The $116,550 contract is for the delivery of Miltefosine, a medication used to treat leishmaniasis and other drug-resistant infections in veterans. The contract has an ultimate completion date of September 30, 2024 and is part of a larger $1,127,000 Blanket Purchase Agreement (BPA)...
This is a firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA) Veterans Integrated Service Network (VISN) 23 to Profounda Inc., a self-certified small disadvantaged business and manufacturer of pharmaceutical products. The $49,950.00 contract is for the delivery of the emergency medication miltefosine (Impavido) to the Minneapolis VA Medical Center. Profounda Inc. has a significant Blanket Purchase Agreement (BPA) with VISN 8 to provide miltefosine on a...